Corneal graft rejection is a major problem in chronic herpetic keratitis (HK) patients with latent infection. A new class of antiviral agents targeting latent and active forms of herpes simplex virus type 1 (HSV-1) is importantly required. Meganucleases are sequence-specific homing endonucleases capable of inducing DNA double-strand breaks. A proof-of-concept experiment has shown that tailor-made meganucleases are efficient against HSV-1 in vitro. To take this work a step forward, we hypothesized that the pre-treatment of human corneas in eye banks using meganuclease-encoding vectors will allow HK patients to receive a medicated cornea to resist the recurrence of the infection and the common graft rejection problem. However, this strategy requires efficient gene delivery to human corneal endothelium. Using recombinant adeno-associated virus, serotype 2/1 (rAAV2/1), efficient gene delivery of a reporter gene was demonstrated in human corneas ex vivo. The optimum viral dose was 3.7 Â 10 11 VG with an exposure time of 1 day, followed by 6 days incubation in de-swelling medium. In addition, 12 days incubation can result in transgene expression in excess of 70%. Using similar transduction conditions, meganuclease transgene expression was detected in 39.4% of the endothelial cells after 2 weeks in culture. Reduction of the total viral load in the media and the endothelial cells of corneas infected with HSV-1 was shown. Collectively, this work provides information about the optimum conditions to deliver genetic material to the cornea, and demonstrates for the first time the expression of meganuclease in human corneas ex vivo and its antiviral activity. In conclusion, we demonstrate that the treatment of human corneas in eye banks before transplantation is a new approach to address the unmet clinical needs in corneal diseases.
INTRODUCTION
Herpetic keratitis (HK) caused by herpes simplex virus type 1 (HSV-1) is a major cause of corneal graft rejection.
1,2 HSV-1 primary infection is asymptomatic, and most of the population in developed countries are carriers of the virus. 3 HK is also a major cause of corneal scarring, and the recurrence of the infection ultimately leads to corneal opacity, neovascularization and irregular astigmatism. 4 The total HSV-1 genome length has been identified in early work by McGeoch et al. 5 to contain 152 260 residues. The genome contains 77 genes as detailed in databases (NC_001806 from http://www.ncbi.nlm.nih.gov). During latency, linear DNA becomes circular or as a large concatemer. [6] [7] [8] Reactivation of the latent virus in the trigeminal sensory neurons innervating the cornea results in corneal allograft rejection in 33% of patients (n ¼ 72) after 2 years of penetrating keratoplasty. 9 HSV-1 was also reported to be at least six times more prevalent after cornea transplantation surgery, 3 but graft survival rates after 5 years of the surgery fell under 50%. 10 Although the corneal graft failure has been reduced significantly during the past decade because of progress of eye banking, operating techniques and better immunosuppressive and antiviral drugs. 2 Thus far, corneal graft rejection rates remain high, where more recent data show that 18.4% of corneal transplantation patients were clinically diagnosed positive for HK; HSV-1 DNA load directly correlated to the corneal graft rejection rates. 11 Accordingly, antiviral agents against only active HSV-1 infection are not sufficient to control the infection and reduce corneal graft rejection rates. Different gene therapy approaches to battle HK and improve graft survival have been recently reviewed. 12 Gene therapy has various advantages over protein-based therapy, being more effective and specific. Protein expression in transduced cells has greater efficacy than what can be achieved by traditional systemic pharmacological approaches. Genome surgery utilizing homologous recombination (HR) mechanisms is, therefore, an attractive tools to minimize random insertion events. HR is a mechanism important for chromosome maintenance and damage repair. It was demonstrated that HR can stop the demise of damaged DNA replication forks, coordinate the separation of homologous chromosomes in meiosis I and functions in telomere maintenance. [13] [14] [15] [16] Deficiency in HR mechanisms can lead to cancer formation, [17] [18] [19] however, HR events can be initiated by artificial substrates with identical sequences within the targeted locus, to allow for genetic editing. Custom-made endonucleases can enhance the efficiency of this process by DNA double-strand breaking with high degree of specificity. 20, 21 Therapeutic applications of meganucleases also include the induction of genome-specific double-strand break in viral genome. Recently, custom-made homing endonucleases, namely meganucleases, emerged as new class of antiviral agents acting as genome scissors. Meganucleases are sequence-specific homing endonucleases recognizing large targets (412b). 22 As a result of their accurate editing of genomes in living organisms, meganucleases are considered a promising tool in genome surgery. Adeno-associated viruses (AAVs) encoding for sitespecific endonucleases and recombination substrates have been successful in inducing HR in vitro. 23, 24 Here we propose the use of a specific meganuclease, HSV-1m2, for the pre-treatment of human corneas ex vivo before transplantation into HK patients to avoid the recurrence of the infection and allograft rejection. HSV1m2 designing and engineering have been described in recent work. 25 HSV-1m2 was designed to target a major capsid component in the long unique region (UL19) of the HSV-1 genome and was chosen for this work for its potent inhibitory effect in recombinant and wild-type HSV-1 infected cells. It was demonstrated that HSV-1m2 significantly reduces gene and protein levels of HSV-1 in vitro. In addition, the viral load was also significantly reduced by 56% at a multiplicity of infection of 10 À 1 . 25 In vitro and ex vivo gene transfer of HSV-1m2 to mice corneas has been recently reported. 26 Interestingly, pre-treatment of mice corneas using HSV-1m2 was shown to be able to protect corneas from wild-type HSV-1 infection induced 3 weeks after transduction. A reduction in the viral load and replication was evident. In addition, an in vivo study showed that HK-like phenotype induced by rHSV-1 can be reversed using HSV-1m2, as recently reported. 27, 28 In this report, we aim at optimizing the delivery of meganuclease to human corneas ex vivo to act as genome scissors to cut the viral genome, and lessen the infection. We demonstrate, using recombinant adeno-associated virus serotype 2/1 (rAAV2/1) vector, that optimizing the transgene expression of HSV-1m2 in human corneas is achievable; hence, corneal transplants can be loaded by HSV-1m2 to protect from recurrent HSV-1 infection and improve graft survival probability. In addition, the ex vivo approach appears feasible to eliminate some of the safety issues involved with in vivo gene transfer.
RESULTS
The effect of post-mortem and preservation time on viability and cell density of the endothelium To assess the effect of the pre-experimental incubation time in organ culture conditions, information from 93 corneas used in our experiments was analyzed. The effect of the post-mortem time (from death to retrieval of the cornea) and the preservation time (from receiving the cornea in eye bank until experimentation) are two variables for this analysis. The endothelial density was recorded when a cornea was received, and 20-30 days afterward. No significant effect of post-mortem time was noted (Table 1) . The loss in the endothelial density was below 25% from the initial count, however, this value did not increase during 28 days (Table 2) .
Transduction of human corneas with a reporter gene In an initial set of experiments carried out to quantify the green fluorescent protein (GFP)-positive cells in human corneas after transduction, 13 corneas were transduced, 10 with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP each and 3 with same quantity of empty vector (rAAV1/2-CMV-non-coding) for 2 days, followed by an incubation period of 2 days. Transduction and incubation were performed using transport media and whole corneas were scanned thoroughly using direct confocal microscopy. Sectioning of corneas was performed for subsequent examination. The counting of endothelial cells was performed using the phase contrast image. The average transduction efficiency in 10 corneas was 4.9 ± 2.6% (Figure 1a ), where GFP expression was detected in and around the nucleus. The stroma of these corneas was always negative for GFP, however, the endothelium showed some positive signals ( Figure 1b) . No signal was detected in the three corneas transduced with non-coding vector. In the 13 corneas used in this experiment, the average age of the donors was 64.9±8.5 years and the average endothelium density was 1846.2 ± 161.3 cells mm -2 .
The transduction was performed after 27.5 ± 2.6 days post-mortem.
Transduction efficiency is higher in transport media
To study the effect of two types of media commonly used in eye banks, corneas were transduced with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP for 2 days followed by either 2 or 4 days incubation. For each set of triplicate corneas, a cornea was transduced using noncoding vector (7.4 Â 10 11 VG). Both transduction and incubation steps were performed either in storage or transport media. The post-mortem time was estimated from the death of a donor until the retrieval of the cornea. The percentage loss in the endothelial density was measured during 24 h post-mortem. The incubation time was estimated from the retrieval of the cornea. The percentage loss in the endothelial density was measured up to 28 days incubation in organ culture.
Dark field Phase contrast DAPI Merged image
Merged image Phase contrast Dark field Figure 1 . GFP expression in human cornea. Transduction of human corneas for 2 days was followed by 2 days incubation in fresh media. Three images were acquired for each of the 13 corneas used in this experiment. A representative image of the 10 corneas, transduced with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP each, is presented (a). Figure 1a shows the dark field (left), phase contrast (middle) and merged image (right). To check for GFP-positive cells in the stroma, transverse sections were used; the lower panel (b) shows the dark field (GFP in green), phase contrast, DAPI-stained nuclei (blue) and merged images from left to right. Images were captured at Â 10 magnification using confocal microscopy.
Transduction efficiencies in storage media were 2.8 ± 2.6% and 36.6 ± 15.8% after 4 days or 6 days, respectively ( Figure 2 ). To decide if the transduction efficiency was low because of the delay in the transgene expression or because of the media used, the previous steps were repeated in storage media (one cornea), and the incubation time was increased to 12 days (total experimental time 14 days). One cornea was transduced with the empty vector for 14 days as well. Transduction efficiency was estimated at 26.6 ± 12.7% after 14 days of the transduction. However, transduction in transport media for 14 days was not performed because a cornea will not remain healthy for 2 weeks in media containing dextran. In transport media, the transduction efficiency was 6.6 ± 0.8% and 53.5 ± 11.9% after 4 and 6 days, respectively (n ¼ 3; Figure 2 ). No signal was detected in corneas transduced with the non-coding vector. These results show that it is possible to transduce corneas while being sent for transplantation, which is a new potential option. For the corneas used in this experiment, the average age of the donors was 64.8±5.6 and the average endothelium density was 1950±116.8 cells mm -2 . The transduction was performed after 25.9 ± 2.8 days from collection.
Optimization of the exposure time To study the effect of the exposure time to the virus on the transduction efficiency of human corneas, the total experimental time was set at 6 days and 3 exposure periods were selected, 1, 2 or 3 days. Nine corneas were transduced with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP for 1, 2 or 3 days (3 per time point). Also a cornea per time point was transduced with the non-coding vector as before. The average transduction efficiency was 41.1 ± 1.95%, 53.53±11.9% and 45.1±6.7% in corneas exposed to the transduction media for 1, 2 or 3 days, respectively (n ¼ 3; Figures  3a and b) . No significant differences were found between the three groups (Pp0.05), however, transduction for 1 day showed more consistent data with less error margin. In the nine corneas used, the average age of the donors was 60.7 ± 9.8 years and the average endothelium density was 1933.3 ± 212.1 cells mm -2 . The transduction was performed after 25.9±2.9 days from collection.
Optimization of the incubation time To study the effect of 4 and 5 days incubation time on the transduction efficiency, three corneas were transduced with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP for 2 days followed by 4 or 5 days of post-transduction incubation periods. The total experimental time was 6 or 7 days. The average transduction efficiency was 53.53 ± 11.9% and 52.7 ± 12.3% (Figures 4a and b) after incubation for 4 and 5 days post-transduction, respectively, with no significant differences. No signal was detected in a non-coding vector transduced cornea. For the six corneas used in this experiment, the average age of the donors was 62.2±5 years and the average endothelium density was 1983.3±172 cells mm -2 .
The transduction was performed after 26.5 ± 2.3 days from collection.
To study the effect of 12 days incubation time on the maximum transduction efficiency, two corneas were transduced in transport media for 2 days, and then incubated in storage media for further 12 days. The total experimental time was 14 days. Transduction efficiency was estimated at 72.3±2.8% in two corneas (Figure 4) , however, the stroma remained negative for GFP-expressing cells (Figure 4c ). The average age of the donors was 58.5 ± 9.2 years and the endothelium density was around 2000 cells mm -2 in both corneas. The transduction was performed after 17.5±5.9 days from collection. These results shows that the incubation of corneas for 6 days is enough to detect the transgene expression in 450% of the endothelial cells, however, extending the time up to 2 weeks, with switching the media to storage media after 2 days can yield 470% transduction efficiency.
Optimization of the viral dose
In order to optimize the transduction conditions, a range of dilutions from the initial viral dose (7.4 Â 10 11 VG) were tested. The range included 1:2, 1:10, 1:100 and 1:1000 dilutions. All corneas were transduced for 2 days followed by 4 days incubation in fresh transport media and the total incubation time for each exposure period was 6 days.
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Storage media
Transport media 6 days Figure 2 . Choice of the transduction media. Transduction of human corneas with 7.4 Â 10 11 VG of rAAV1/2-CMV-GFP each for 2 days, followed by 2 or 4 days incubation in either storage or transport media, as labeled. A representative image for each group of nine images from three corneas is presented. GFP transgene expression is in green. Images were captured at Â 10 magnification using confocal microscopy. . The transduction was performed after 26.2 ± 4.4 days from the retrieval of the cornea from the donor.
Transgene expression in the stroma Many reports have described the latency of HSV-1 virus in the stroma, rather than the trigeminal ganglia, hence, we attempted to improve the vector's accessibility to the stroma. In all our experiments, the stroma was rarely positive for GFP. To improve the gene delivery of rAAV2/1 CMV-GFP vector to the stroma, we developed a technique based on optical coherence tomography. One cornea (Figure 6a ) was excised using a microkeratome fitted with an optical coherence tomography commonly used in eye banks. Posterior part thickness was around 50 mm, containing the full thickness of the endothelium and a thin layer of the stroma (Figure 6b ). These measures can be modified according to requirements. The cornea was then transduced with 7.4 Â 10 11 VG of the GFP-encoding vector as described in Materials and methods section. All steps were performed in transport media and the cornea was incubated with the transduction media for 2 days, followed by 4 days incubation in fresh media. GFP-positive cells were detected in the endothelium (Figure 6d) . Transduction of the stroma was evident, however, a precise count was not performed (Figure 6c ).
Long-term viability of donated human corneas
To study the effect of prolonged tissue culture periods and/or meganuclease transduction on the endothelial density and viability of the tissue, three corneas were used 1 day after collection from donor, and then stored in an organ culture incubator. Corneas were inspected every 7 days for a total experimental time of 28 days.
No mortality was detected using Trypan blue dye in the three tested corneas on day 1, and this did not change during the 28 days of the experiment. The endothelial density was showing a trend toward decrease after 21 days, which was significant after 28 days (P ¼ 0.017). Although no mortality was detected, the average survival rate was estimated 73.3 ± 15.1%, based on the endothelium density changes (Figure 7a) .
Four other corneas were inspected for endothelial density and mortality, and then transduced using 3.7 Â 10 11 VG ml -1 of rAAV2/1-pCMV-mHSV2. Corneas were incubated with the transduction media for 1 day, followed by incubation in storage media at 37 1C. The total experimental time was 14 days. Following this transduction procedure, the endothelial density and mortality were examined on days 7 and 14. At each time point, the endothelial density was calculated from three different areas. The endothelial percentage mortality was estimated using Trypan blue dye. The average total experimental time in this experiment was maintained below 1 month.
In the meganuclease-expressing corneas and after 1 day of the experiment, all corneas had moderate morphology (common irregularities in cell shape and borders). After a week in culture, the endothelium density was reduced by 9.9±7.7%, however, the reduction was not significant as compared with day 1 (P ¼ 0.068). After 2 weeks, 27.9 ± 9% loss of the endothelial cells was significant (P ¼ 0.012; Figure 7b ) and the average mortality was estimated at 4.5±5.9% in the four corneas. The average age of the three donors of the four corneas was 59.6 ± 9.2 years and the endothelium density was 1966.7 ± 152.8 cells mm -2 . The transduction was performed after 16±6.2 days from collection. Corneas expressing meganuclease were not incubated for 414 days to prevent the interference of the decline in the endothelial density (after 2 weeks) due to the incubation time or the transduction process. In addition, the HSV-1m2 expression was abundant in the four corneas (results not shown).
Quantification of the meganuclease expression in the endothelium The HSV-1m2 is able to induce double-strand cut in the HSV-1 genome in the position indicated in Figure 8a . To deliver, detect and quantify the meganuclease expression in the endothelium of human corneas ex vivo, the conditions yielding maximum GFP expression were used. The first attempt was to transduce human corneas for 2 days using 7.4 Â 10 11 VG ml -1 of rAAV2/1-pCMVmHSV2 vector, followed by 4 days incubation. The endothelium was separated before immunohistochemistry (IHC) by the airbubble method (Figure 8b) as detailed in the Materials and methods section. The average transduction efficiency in nine corneas was 13.8±8.3% (Figures 8c and d) . Reducing the transduction period to 1 day in transport media, and increasing the total incubation time to 13 days in storage media, the transduction efficiency increased significantly (Pp0.001) to 39.4±9.7% in six corneas (Figures 8c and d) . The average age of the donors of the corneas was 64.9 ± 6.9 years and the endothelium density was around 2044.4 ± 212.8 cells mm -2 . The transduction was performed after 22.3±2.7 days from collection. In addition, performing all steps in storage media showed mostly inconsistent data, with the transduction efficiency ranging between 68±2.4% and 4.3±1.5% in three corneas after 14 days of incubation. The post-mortem time was also reduced to 15.6 ± 4.1 days from collection date. No signals were detected in two corneas transduced with non-coding vector. Transgene expression was in patches, similar to the expression pattern of GFP. The fluorescence was detected in cell groups usually on the folds of the endothelium and more evident on the periphery of the cornea.
Infection of human corneas with HSV-1
The activity of meganuclease (HSV1m2) against HSV-1 was investigated in three pairs of corneas from three donors.
GFP
Phase contrast DAPI Merged Low post-mortem time was ensured in order to be able to transduce corneas for 2 weeks followed by 2 days post-infection. Each donated pair was transduced with non-coding vector (controls) or meganuclease HSV1m2 encoding rAVV2/1-CMV vector as detailed in the Materials and methods section. At 48 h post-infection, corneal supernatants were used to perform a plaque assay and a quantification of total viral genome using real time PCR. The plaque assay showed a decrease by 23.8% (n ¼ 3) in the viral titer in the supernatants collected from HSV1m2-treated corneas as compared with controls ( Figure 9a ). The total viral DNA in those samples was also reduced by 37% (Figure 9b) . The viral genome quantified within the endothelial cells of two HSV1m2-treated corneas displayed an even more significant reduction (up to 76.1%) in the amount of viral DNA as compared with corresponding negative controls (Figure 9b) . A pair of corneas was used to verify the expression of meganuclease and to analyze the HSV-1 infection by immunofluorescence. The cornea expressing HSV1m2 showed a reduction in the number of GFP-positive cells and also the fluorescence intensity (Figure 9c ). The average age of the donors of the corneas was 69±6.2 years and the endothelium density was around 2033.3 ± 115.5 cells mm -2 . The transduction was performed after 4.3 ± 2.5 days from collection.
DISCUSSION
The delivery of an appropriate amount of therapeutic genes into the target tissue, with minimal toxicity, lies in the heart of gene therapy success. Gene therapy for the corneal endothelium is, at present, principally aimed at improving the quality of donor corneas. Recent data, for example, suggest that the endothelium of human corneas treated with the anti-apoptotic gene p35 survives longer than untreated cells. 29 Clinical advances in gene therapy have shown that viral vectors can deliver genes safely to several tissues and the promising initial results from a number of clinical trials suggest that certain diseases may potentially be treatable.
Successful delivery of therapeutic meganucleases to human corneas ex vivo was achieved here for the first time, highlighting the possibility of delivering genetic material or therapeutic molecules to the corneal endothelium using non-integrating rAAV2/1. We have shown that excellent delivery of GFP to human corneas can be achieved after 2 weeks in culture. The toxicity of the viral vector was minimal; however, improvements in the specificity and transduction conditions can marginalize this effect. Nuclease toxicity can be reduced, for example, by the addition of drug-responsive destabilization domains 30 to engineer meganucleases with different residue in the DNA-binding sequences. This approach was successful in the attenuating the toxicity of zinc-finger nucleases but yet not performed in the field of custom meganuclease engineering. Other classes of sequencespecific DNA nucleases capable of generating double-strand breaks include the transcription activator-like effector nucleases and zinc-finger nucleases. [31] [32] [33] These classes, alongside meganuclease, can potentially be investigated for their antiviral applications.
We have also demonstrated that the incubation of human corneas in the transduction media for 1 day is enough to achieve a reasonable transgene expression. No significant differences were noted between 1, 2 and 3 days exposure to the transduction media. Therefore, 1 day or less transduction period is recommended to reduce the exposure time to the virus and reduce cytotoxicity. This is also consistent with a recent study showing that 24-to 30-h incubation in de-swelling media did not result in endothelial cells loss or mortality. 34 In our hands, the viral dose of 3.7 Â 10 11 VG consistently yielded good and reproducible transduction efficiency in 450% of the endothelial cells. Therefore, it is recommended to explore further dilutions of this dose to minimize the toxicity. Dilution of the viral dose to more than a 100 times reduced the transduction efficiency significantly.
The incubation of human corneas in storage media (organ culture) for 43 weeks post-mortem, will decrease the endothelial cell density, however, no mortality was noted. Therefore, up to 25% loss of endothelium can be considered normal under organ culture conditions. Nonetheless, extended experimental time (430 days in this case) will contribute to the endothelial cell loss, and interfere with transduction results. Thus, it is recommended to perform all steps within the first 3 weeks post-mortem, to eliminate the effect of a prolonged incubation time. Most of the corneas used for this work were between 15 and 21 days postmortem (27 corneas) because of the good availability of tissue within this range. However, the microbiology testing of corneas before releasing for transplantation or research takes 6 days. Few corneas used with a post-mortem time of o7 days were contraindicated for transplantation for non-infective or genetic diseases in most cases. Those corneas are dedicated straight away for research. To perform the viral infection of human corneas, six corneas from three donors, and four sets of experiments were used to evaluate the antiviral activity of HSV1m2 meganuclease. Our data clearly show that the delivery of HSV1m2 meganuclease by rAAV2/1 transduction of corneas reduced the number of HSV-1 genome copies in the infected corneas as well as the replication of the virus as determined by plaque assay and real-time PCR. Our results are consistent with the data reported in the literature on the antiviral mechanism of HSV1m2 meganuclease 25 and thus give further functional relevance to our study. In addition, pair of corneas from the same donor was used to test untreated versus HSV1m2-treated corneas with minimal interpersonal variations. Corneas with low post-mortem time and high endothelium density were used (around 1 week) for this experiment. Statistical analysis showed that the power of test can be 95% if we use 12 pairs of corneas. However, obtaining this number of precious human tissue with these strict demands was not possible. Of note, the post-mortem time (time from death to tissue collection) up to a day is suitable for collecting human corneas and the loss in the endothelial density is negligible. Although 22.5-25% loss in the endothelium density is expected after the first week in organ culture, preserving the cornea in storage media for up to 4 weeks did not result in further loss. Our data also show that transduction of human corneas in de-swelling media gives better transduction efficiency than in conventional storage media (without dextran), however, differences were not significant because of low reproducibility of the results in the set of replicates, not to mention variations in human tissue from a donor to another. This can be attributed to the effect of dextran on the endothelium layer of the cornea; the movement of solute and fluid from the aqueous humor to the stroma and vice versa is controlled by corneal hydration mechanisms. De-swelling agents can cause changes in the endothelial cells' morphology, density and permeability. The de-swelling rate was found to be proportional to the endothelial permeability. 35 Therefore, it is hypothesized that the de-swelling of the endothelial cells can aid in the uptake of the virus from the transduction media. In addition, the viscosity of the media increases when dextran is added, which may limit the mobility of the virus. rAAV2/1 was chosen for this study for its success in vivo, in vitro and ex vivo studies in rabbits and mice. [26] [27] [28] Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. In some cases, such as genetic disorders, extended expression period in a minor population of cells is sufficient, whereas other pathologies might require transient gene expression in a larger population of cells.
In the absence of helper virus, AAV was shown to initiate latency mechanisms by integrating in a specific site, namely AAVS1, in the human chromosome 19q13.3-qter. 36 This occurs through an interaction between the inverted terminal repeats and the AAVS1 locus mediated by the Rep protein involved in the life cycle of the virus. 37 Despite the presence of a preferential integration site, the status of AAV genomes from infected cells has been shown to be mainly episomal. 38 The adaptation of an AAV into recombinant vector (rAAV) to be used in gene therapy is achieved by replacing the viral coding sequence between the inverted terminal repeats by the therapeutic gene. 39 The process of rAAV production, involving the rep and cap and other helper genes is detailed elsewhere. 40 In the absence of Rep, rAAV loses its site-specific integration ability. 41 Compared with other viral vectors, rAAV induces little or no innate immunity, probably due to the lack of viral sequence other than the inverted terminal repeats. 42 In addition, rAAV generally elicits a reduced cellular immunoresponse against the transgene product, probably due to the inability of rAAV vectors to efficiently transduce or activate mature antigen-presenting cells. 43 Humoral and cell-mediated immunity to transgenes depends on a number of variables including the nature of the transgene, the promoter, the route and site of administration, the vector dose and the host factors. [43] [44] [45] The majority of these variables can be suitably modified. One of the major negative aspects of rAAV vectors as tools for in vivo gene transfer is their relatively small packaging capacity (4.7 kb). This can limit the use of rAAV vectors to correct mutations in large genes. Despite this limitation, the absence of human diseases associated with their infection, the low toxicity and immunogenicity, the ability to transduce both dividing and non-dividing cells and the possibility to use a specific serotype to transduce a target tissue make rAAV an ideal candidate vehicle for gene therapy applications in vivo.
Different rAAV2 serotypes have recently been shown to have different tropism in equine joint tissues. 46 In addition, the expression profile of the rAAV1/2 virus shows comparably late expression peak; the transduction of human corneas with rAAV1/2 is progressively induced with longer incubation periods. We demonstrate that the transduction efficiency after 6 days was significantly higher than 4 days. Moreover, incubation for further 12 days improved the transduction efficiency significantly. Although the intrahypothalamic injection of rAAV2-1 vector was recently shown to maintain an abundant transgene expression for 43 months in vivo, 47 the onset of rAAV2/1-mediated transgene expression was found to be after 4 days, with no change in gene expression during 14 days in rats in vivo. 48 However, in human polarized airway epithelia, the expression of transgene was evident after 1 day. 49 Similar results were obtained by another group, using rAVV2 serotype, they were able to demonstrate GFP transgene expression in 490% of the human corneal endothelium after exposure to the virus for 1 day, followed by 2 weeks in culture, 50 however, the counting procedure remains a main concern. The transduction efficiency of the corneal endothelial cells can be estimated using several counting methods including counting cells using the phase contrast settings in a confocal microscope or by the calculation of the number of cells in a certain area (cells per mm 2 ), which is routinely done in eye banks using a light microscope fitted with a lens with a grid. Another method is to use a standard fixed value representing the average cells per mm 2 in a given area. In the later approach, however, a large number of corneas should be used to calculate the universal cell density value and then this value should be adopted as a constant standard reference. Counting GFP-negative and GFP-positive cells using confocal microscopy is more accurate than the other two methods; however, trivial transgene expression undetectable by IHC or direct fluorescence can be better detected by quantitative methods such as real-time PCR. Of note, transverse sections have been useful in the visualization of fluorescence in the stroma; however, determination of the percentage transduction in keratocytes was not possible due to high variation between sections. In addition, the detection of GFP-positive cells using z-stack (images of planes at various depths) was not accurate because of the thickness of the tissue, where the examined field was always out of focus.
Although corneal graft survival rates in patients diagnosed with HK can be improved using modern surgical procedures, such as deep anterior lamellar keratoplasty, 51 yet, the need is increasing for a new class of antiviral agents to target both, latent and active HSV-1, and reduce the viral load. In addition, the latency of HSV-1 in the stroma is an ongoing debate, raising the necessity for slow release anti-HSV-1 agent from the endothelium, as a slow dividing tissue. Therefore, meganucleases emerge as a novel class of antiviral agents, and HSV1m2 represents a promising prototype to be furtherly developed. The possibility of providing HSV-1-resistant corneas for transplantation will be a major achievement in gene therapy and a step forward to reduce failure rates in cornea transplantation.
In conclusion, this work will contribute to the progress in the development of gene therapy approaches for corneal diseases. It confirms the possibility to treat human cornea ex vivo within eye banks, using rAAV2/1 vector in this case, to express therapeutic proteins in the endothelium and the stroma. This safer way of treatment can be applied to endonucleases targeting HSV-1 and opens the door wide to other essential solutions in the 'medicated cornea' transplantation field.
MATERIALS AND METHODS
Transduction of human cornea
Corneas are usually transported from hospitals to eye bank and back to hospital for transplantation in a de-swelling media (with dextran) to prevent excessive swelling of the cornea. This type of media is termed 'transport media'. The transport media is prepared using minimum essential media 95% v/v (Life Technologies, Monza, Italy), sodium pyruvate 1% (Life Technologies), L-glutamine 1% (Life Technologies), penicillin/ streptomycin 1% (Sigma-Aldrich, Milan, Italy), new born calf serum 2% (Life Technologies) and dextran t500 6% (Pharmacosmos, Padova, Italy). For the storage of corneas in eye banks, the media used is usually without dextran, and is termed 'storage media'. The storage media composition is similar to the transport media, but without adding the de-swelling agent; dextran t500. The endothelial density in all corneas was 1500-2100 cells mm -2 unless otherwise stated. Corneas kept in storage media at 31 1C were reshaped (recommend diameter is 8-10 mm) to fit 1-well of a 24-wells plate (cat. no. 3524; Corning S.r.l, Milan, Italy). Washing in phosphatebuffered saline (1X PBS; 14200-067; GIBCO, Life Technologies) was performed before replacing the media (1 ml per well). Viral particles recommended count was initially set at 7.4 Â 10 11 VG of either rAAV1/2-CMV-GFP, rAAV1/2-CMV-mHSV2 or rAAV1/2-CMV-non-coding per cornea in 1 ml of transport (de-swelling) media containing dextran. A range of concentrations was tested as indicated in the results section. Corneas were submerged in 1 ml of transport media endothelium side-up, however, different media were tested as detailed in the results section. Corneas were incubated with the transduction media for 2 days. Rinsing twice by immersion in 5 ml PBS, was followed by another 2 days incubation in fresh media. Incubations in all experiments were carried out at 37 1C. Separation of the endothelium by the air-bubble method Examination of samples was performed using a confocal microscope (Zeiss LSM-510 meta, Carl Ziess, Oberkochen, Germany), sections with thickness of 5-20 mm is optimum for best resolution of images. This is a new application for the air-bubble method 52 to be used for the first time in IHC to improve penetration and staining. Immunostaining was performed only on the endothelial layer of the cornea to facilitate the access of antibodies and enhance the staining process. A 25-gauge (or thinner) syringe was used to inject air underneath the Descemet's membrane and the endothelium, to create an air bubble between the endothelium and the stroma. The endothelium is then excised using straight a Noyes iris scissors and a Graefe's fixation forceps (Figure 8b ). The detection of the transduction efficiency in one cornea showed around 50% improvement in the detection efficiency of GFP (10.6% versus 20.8%; results not shown). The technique is based on the separation of the Descemet's membrane from the stroma by air pressure (Figure 8b ). After IHC, the endothelium is excised and preserved on a slide using VECTASHIELD Hard þ Set Mounting medium with DAPI (Vector Laboratories, Youngstown, OH, USA). Lamellar keratectomy for transducing the stroma was performed using Moria evolution 3 microkeratome and a TOMEY optical coherence tomography (Tomey Corporation, Nagoya, Japan).
Tissue fixing and histology
Human tissue was rinsed twice in PBS then submerged in 4% paraformaldehyde freshly prepared each time and stored at 4 1C overnight. Sectioning of samples was performed using conventional microtome (Leica, Milan, Italy). Transitional sections were included in optical coherence tomography (Cryobloc) purchased from Diapath, Martinengo, Italy (cat. no. 070130). Menzel SuperFrost plus slides from Diapath (cat. no. 060SFP) were used for collecting sections. Samples were then snap frozen in the -80 1C freezer for 30 min.
Immunohistochemistry
Corneas fixed overnight at 4 1C in 4% paraformaldehyde were rehydrated by washing twice in PBS. Incubations were always in a shaking incubator (31 1C) unless otherwise stated. The endothelium was separated by airbubble method and permeabilization of the samples was achieved using PBS containing 0.5% Triton for 15-20 min in the shaking incubator. Samples were then washed three times, 15 min each, with PBS. Samples were blocked using 2% goat serum (cat. no. G9023-10ML; Sigma-Aldrich) for 2 h and then the primary antibody (1:100 in PBS) was incubated with samples overnight. The secondary antibody (1:100 in PBS) containing 20% goat serum was incubated with the samples for 2 h after washing in PBS for 45 min, changing the media every 15 min. The washing step was also repeated after the incubation period with PBS.
The primary antibodies were rabbit polyclonal anti-meganuclease (CLS_atb_Ab_Rabbit_Polyclonal anti I-Cre I histag-Batch L08101/ G27123/J112) supplied by Cellectis, mouse monoclonal anti-meganuclease (AntiMeganuclease-mAb-3, 01162010-005A, IgG1-PURIFIED-4,3 mg ml 
Confocal microscopy
Direct fluorescence (GFP) or fluorescence after IHC was examined using LSM 510-meta laser scanning microscope. The tissue was examined under ultraviolet light or at fluorescence wavelength of 488 or 594 nm. The endothelium was routinely checked at least in three different fields within the transplantation disc (8-10 mm). Three counts were taken per field, and three images from three different fields were acquired. In depth examination using z-stack was performed to examine the concave surface of cornea, however, after introducing the separation of the endothelium as a new technique to improve IHC, this method was abandoned. Reproducibility of the IHC protocol was assessed by evaluating qualitatively the consistent staining using positive controls against actinconjugated fluorescence. The phase contrast image was routinely used to count the number of cells within a certain area, and then the fluorescence filter was used to detect fluorescence in the same field.
Infection with HSV-1
Cornea pairs were transduced with either, 3.7 Â 10 11 VG ml -1 rAAV2/1-pCMV-non-coding or rAAV2/1-pCMV-mHSV2. Corneas were incubated with the transduction media for 1 day, followed by incubation in storage media at 37 1C for further 13 days. Following this transduction procedure, the corneas were infected with HSV-1-GFP as previously described. 53 Briefly, each cornea was infected with 1 Â 10 4 plaque-forming units of the GFPexpressing recombinant virus V41 (kindly provided by Professor Peter O'Hare 54 ) for 1 h at 37 1C. After viral absorption, corneas were washed three times with PBS warmed up to room temperature and maintained in 3.5 ml storage medium. Two days post-infection, supernatants were collected and the cellular debris were removed by centrifugation at 1200 Â r.p.m. for 7 min at 4 1C. Supernatants from each cornea (250 ml) were used to perform a plaque assay on Vero cells, as already described. 25 In addition, viral DNA was extracted from supernatants by automated nucleic acid extraction system and quantified by HSV-specific Real-Time PCR assay. The endothelium was separated as described in section Immunohistochemistry. Two pairs of corneas were used for DNA extraction from the endothelium, and a pair for immunofluorescence (procedure described in section Immunohistochemistry). The total HSV-1 genome was quantified using quantitative PCR.
